Programmed Death-Ligand 1 Expression Across Multiple Assays in Ovarian Cancer: A Comparative Analysis
The expression of PD-L1 in ovarian cancer varies across assays and scoring methods, emphasizing the need for standardized testing protocols. Increased PD-L1 expression post-chemotherapy underscores the importance of assessing its status at appropriate times to guide ICI therapy. Larger studies are required to validate these findings and refine clinical applications.
Authors
- Eun Bi Jang
- So Dug Lim (ORCID: https://orcid.org/0000-0003-2036-0313)
- Wan Seop Kim (ORCID: https://orcid.org/0000-0001-7704-5942)
- Wook Youn Kim (ORCID: https://orcid.org/0000-0003-4024-8791)
- Heejin Bang (ORCID: https://orcid.org/0000-0001-5357-5025)
- Kyeong A So (ORCID: https://orcid.org/0000-0002-3566-8436)
- Tae Jin Kim (ORCID: https://orcid.org/0000-0001-9802-0568)
Institutions
- Konkuk University (KR)
- Konkuk University Medical Center (KR)
Publication Details
- Journal
- Cancer Research and Treatment
- Published
- 2025-06-09
- DOI
- https://doi.org/10.4143/crt.2025.202
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Korea Health Industry Development Institute